Previously submitted to: JMIR mHealth and uHealth (no longer under consideration since Jan 18, 2022)
Date Submitted: Jun 24, 2021
Open Peer Review Period: Jun 24, 2021 - Aug 19, 2021
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
High national acceptance for COVID-19 contact tracing technologies in Taiwan
ABSTRACT
Background:
Governments worldwide have introduced COVID-19 tracing technologies. Taiwan, a world leader in controlling the virus’ spread, has introduced the Taiwan ‘Social Distancing App’ to facilitate COVID-19 contact tracing. However, for these technologies to be effective, they must be accepted and used by the public.
Objective:
Our study aimed to determine public acceptance for three hypothetical tracing technologies: a centralized Government App, a decentralized Bluetooth App (e.g., Taiwan’s Social Distancing App), and a Telecommunication tracing technology; and model what factors contributed to their acceptance.
Methods:
Four nationally representative surveys were conducted in April 2020 sampling 6,000 Taiwanese residents. Perceptions and impacts of COVID-19, government effectiveness, worldviews, and attitudes towards and acceptance of one-of-three hypothetical tracing technologies were assessed.
Results:
Technology acceptance was high across all hypothetical technologies (67% - 73%) and improved with additional privacy measures (82% - 88%). Bayesian modelling (using 95% highest density credible intervals) showed data sensitivity and perceived poor COVID-19 policy compliance inhibited technology acceptance. By contrast, technology benefits (e.g., returning to activities, reducing virus spread, lowering the likelihood of infection), higher education, and perceived technology privacy, security, and trust, were all contributing factors to overall acceptance. Bayesian ordinal probit models revealed higher COVID-19 concern for other people than for one’s self.
Conclusions:
Taiwan is currently using a range of technologies to minimize the spread of COVID-19 as the country returns to normal economic and social activities. We observed high acceptance for COVID-19 tracing technologies among the Taiwanese public, a promising and necessary finding for the successful introduction of Taiwan’s new ‘Social Distancing App’. Policy makers may capitalize on this acceptance by focusing attention towards the App’s benefits, privacy and security measures, making the App’s privacy measures transparent to the public, and emphasizing App uptake and compliance among the public. Clinical Trial: Not applicable.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.